Comment from Rejuvenation Technologies

Summary: Rejuvenation Technologies, a biotechnology company, supports the draft guidance but requests specific clarifications to ensure the Plausible Mechanism Framework includes therapies for multi-gene convergent conditions like telomere biology disorders. They argue that the current language focusing on single genetic variants might inadvertently exclude treatments that address a common downstream mechanism across multiple genes.